Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217422 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL19681566 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL30781683 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL19401854 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL30985974 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL14931048 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL13984666 | 1.00 | CA2 (0.39) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL19127324 | 0.88 | ALDH1A1 (0.40) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL20520311 | 0.88 | ALDH1A1 (0.40) | CA2ALDH1A1TSHRDDAH1CHEK1 | |
| SCHEMBL7367910 | 0.88 | ALDH1A1 (0.40) | CA2ALDH1A1TSHRDDAH1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103367-A1 | LIGAND-DRUG CONJUGATE, LINKER FOR CONJUGATION, AND USE THEREOF | 海南先声再明医药股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| EP-4455164-A1 | ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024096577-A1 | COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME | 앱티스 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096564-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTI-CLAUDIN-18.2 ANTIBODY, AND THERAPEUTIC USE THEREOF FOR CANCER | 앱티스 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-115969996-A | Antibody drug conjugates and uses thereof | 百奥泰生物制药股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| CN-115429893-A | Drug conjugates and uses thereof | 百奥泰生物制药股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114173824-A | Antibody drug conjugates | 武田药品工业株式会社 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | CA2 2323/4885ALDH1A1 927/4885TSHR 2089/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | CA2 4448/4885ALDH1A1 4069/4885TSHR 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.